Replies to post #196926 on Biotech Values

[DewDiligence]

Reuters update on SNY’s planned divestitures says only the EU portion of SNY’s generic-drug business is being considered (as well as the Merial animal-health unit):

http://www.reuters.com/article/2015/11/27/us-sanofi-m-a-lazard-idUSKBN0TG23F20151127#tRg0IPSuDEAEFRt1.97

[Merial], which employs around 6,500 people, expects to exceed 2.4 billion euros in sales this year. Sanofi could favor an initial public offering for Merial as any takeover attempts by industry rivals would face antitrust challenges, a banker familiar with the matter said. Merial competes head to head with Pfizer's former animal health business Zoetis…

Sanofi could also pursue an outright sale of its European generics business, worth up to 3 billion euros. But any process would only start in the second half of 2016 due to the lengthy legal work needed to disentangle the European business from its global operations, the sources said. Sanofi's global generics unit had overall sales of 1.8 billion euros in 2014.